Linifanib(CAS: 796967-16-3)

Linifanib (CAS: 796967-16-3) is a crystalline compound with a molecular weight of approximately 373.33 g/mol. It has a melting point of about 140°C and is sparingly soluble in water but soluble in organic solvents such as DMSO and methanol. Linifanib is a potent inhibitor of multiple receptor tyrosine kinases, including VEGFR, PDGFR, and FGFR. It is reactive towards electrophiles and can undergo hydrolysis under basic conditions.

Linifanib (CAS: 796967-16-3) can be synthesized through multi-step organic synthesis involving protection, functional group manipulation, and coupling reactions. Commonly used catalysts include palladium and copper complexes. The synthetic route typically involves the formation of key intermediate linkages and subsequent derivatization steps. The overall yield of the synthesis is around 40-50%, with high selectivity towards the desired product.

Linifanib (CAS: 796967-16-3) is primarily used in the pharmaceutical industry for the treatment of certain types of cancer, such as renal cell carcinoma and gastrointestinal stromal tumors. It is also explored for its potential applications in other medical fields, including ophthalmology. Linifanib has shown promise in the development of new drug delivery systems and biosensors.

When handling Linifanib (CAS: 796967-16-3), it is important to wear appropriate personal protective equipment (PPE) such as gloves, goggles, and a lab coat. Work should be conducted in a fume hood to minimize inhalation risk. Spills should be cleaned up immediately using appropriate absorbents. Ensure proper ventilation and store the compound in a cool, dry place away from heat and direct sunlight. Refer to the Safety Data Sheet (SDS) for detailed handling and disposal information.